Regulation of monocyte chemoattractant protein-1 through angiotensin II type 1 receptor in prostate cancer.

[1]  E. Kikuchi,et al.  Phosphorylated Akt up‐regulates angiotensin II type‐1 receptor expression in castration resistant prostate cancer , 2011, The Prostate.

[2]  S. Umemura,et al.  Regulation of androgen receptor expression through angiotensin II type 1 receptor in prostate cancer cells , 2011, The Prostate.

[3]  K. Aozasa,et al.  Infiltration of tumour‐associated macrophages in prostate biopsy specimens is predictive of disease progression after hormonal therapy for prostate cancer , 2011, BJU international.

[4]  Songbin Fu,et al.  Angiotensin II/angiotensin II type I receptor (AT1R) signaling promotes MCF‐7 breast cancer cells survival via PI3‐kinase/Akt pathway , 2010, Journal of cellular physiology.

[5]  Y. Lotan,et al.  Association of angiogenesis related markers with bladder cancer outcomes and other molecular markers. , 2010, The Journal of urology.

[6]  K. Pienta,et al.  Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth. , 2010, Journal of the National Cancer Institute.

[7]  K. Pienta,et al.  CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis. , 2010, Cytokine & growth factor reviews.

[8]  C. Yeo,et al.  Angiotensin II Regulates the Expression of Monocyte Chemoattractant Protein-1 in Pancreatic Cancer Cells , 2009, Journal of Gastrointestinal Surgery.

[9]  E. Kikuchi,et al.  Ets‐1 and hypoxia inducible factor‐1α inhibition by angiotensin II type‐1 receptor blockade in hormone‐refractory prostate cancer , 2009, The Prostate.

[10]  A. Jemal,et al.  Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.

[11]  J. Kinoshita,et al.  Local angiotensin II-generation in human gastric cancer: correlation with tumor progression through the activation of ERK1/2, NF-kappaB and survivin. , 2009, International journal of oncology.

[12]  J. Ricarte-Filho,et al.  Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer. , 2008, Endocrine-related cancer.

[13]  Jaclyn H Neo,et al.  The renin-angiotensin system and malignancy. , 2008, Carcinogenesis.

[14]  P. Allavena,et al.  Cancer-related inflammation , 2008, Nature.

[15]  Zhao-You Tang,et al.  High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Jae Hyun Kim,et al.  High tumour islet macrophage infiltration correlates with improved patient survival but not with EGFR mutations, gene copy number or protein expression in resected non-small cell lung cancer , 2008, British Journal of Cancer.

[17]  B. Sun,et al.  Angiotensin AT1 receptor antagonists exert anti‐inflammatory effects in spontaneously hypertensive rats , 2007, British journal of pharmacology.

[18]  Matthew J. Craig,et al.  Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo. , 2007, Cancer research.

[19]  K. Pienta,et al.  The evolving biology and treatment of prostate cancer. , 2007, The Journal of clinical investigation.

[20]  Matthew J. Craig,et al.  CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration. , 2007, Neoplasia.

[21]  Matthew J. Craig,et al.  CCL2 (Monocyte Chemoattractant Protein-1) in cancer bone metastases , 2007, Cancer and Metastasis Reviews.

[22]  D. Galson,et al.  Monocyte chemotactic protein‐1 (MCP‐1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion , 2006, The Prostate.

[23]  E. Kikuchi,et al.  Angiotensin II Type 1 Receptor Antagonist Candesartan as an Angiogenic Inhibitor in a Xenograft Model of Bladder Cancer , 2006, Clinical Cancer Research.

[24]  D. Troyer,et al.  Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation. , 2005, Endocrine-related cancer.

[25]  J. Egido,et al.  Inflammation and angiotensin II. , 2003, The international journal of biochemistry & cell biology.

[26]  A. Miyajima,et al.  Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis. , 2002, Cancer research.

[27]  T. Wheeler,et al.  Reduced infiltration of tumor-associated macrophages in human prostate cancer: association with cancer progression. , 2000, Cancer research.

[28]  A. Poustka,et al.  Differential transcriptional regulation of the monocyte-chemoattractant protein-1 (MCP-1) gene in tumorigenic and non-tumorigenic HPV 18 positive cells: The role of the chromatin structure and AP-1 composition , 2000, Oncogene.

[29]  U. Kikkawa,et al.  Activation of Akt/protein kinase B after stimulation with angiotensin II in vascular smooth muscle cells. , 1999, American journal of physiology. Heart and circulatory physiology.

[30]  L. Mazzucchelli,et al.  Monocyte chemoattractant protein-1 gene expression in prostatic hyperplasia and prostate adenocarcinoma. , 1996, The American journal of pathology.

[31]  W. Catalona,et al.  Management of cancer of the prostate. , 1994, The New England journal of medicine.

[32]  Y. Oshika,et al.  P-glycoprotein-mediated acquired multidrug resistance of human lung cancer cells in vivo. , 1996, British Journal of Cancer.

[33]  L. Tanoue.  Cancer Statistics, 2009 , 2010 .

[34]  E. Kikuchi,et al.  Angiotensin II type 1 receptor antagonist as an angiogenic inhibitor in prostate cancer , 2007, The Prostate.